Achieved first full year of net income profitability in 2025, driven by 13% revenue growth and 30% adjusted EBITDA expansion despite industry-wide prescription unit declines of 6%. Performance attribution stems from record store expansion and increased penetration of high-value progressives, which reached 22% of prescription units compared to the 40% industry average. Management identifies a 'period of transition' in the optical industry, noting transient softness and demand volatility in the post-pan ...